INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.418 USD | -4.19% |
|
-4.19% | -13.01% |
| 08/05 | InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 21/03 | Transcript : InflaRx N.V. - Special Call |
Presenter SpeechJordan Zwick (Executives)Hello, thank you for joining us at our virtual R&D ev...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
05/06/2024
- R&D Day
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.319
EUR
Average target price
8.375
EUR
Spread / Average Target
+535.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.01% | 84.2M | |
| +8.92% | 114B | |
| +10.48% | 105B | |
| -6.45% | 23.83B | |
| -3.64% | 21.73B | |
| -10.28% | 18.1B | |
| -42.36% | 16.34B | |
| -14.45% | 16.13B | |
| +3.76% | 13.75B | |
| +28.94% | 11.76B |
- Stock Market
- Equities
- IFRX Stock
- News InflaRx N.V.
- Transcript : InflaRx N.V. - Special Call
